Back to Search
Start Over
VDX-111 targets proliferative pathways in canine cancer cell lines.
- Source :
- PLoS ONE; 5/21/2024, Vol. 19 Issue 5, p1-16, 16p
- Publication Year :
- 2024
-
Abstract
- VDX-111 (also identified as AMPI-109) is a vitamin D derivative which has shown anticancer activity. To further assess the function of this compound against multiple cancer types, we examined the efficacy of VDX-111 against a panel of 30 well characterized canine cancer cell lines. Across a variety of cancer types, VDX-111 induced widely variable growth inhibition, cell death, and migration inhibition, at concentrations ranging from 10 nM to 1 μM. Growth inhibition sensitivity did not correlate strongly with tumor cell histotype; however, it was significantly correlated with the expression of genes in multiple cell signaling pathways, including the MAPK and PI3K-AKT pathways. We confirmed inhibition of these signaling pathways as likely participants in the effects of VDX-111. These results suggest that a subset of canine tumors may be sensitive to treatment with VDX-111, and suggests possible predictive markers of drug sensitivity and pharmacodynamic biomarkers of drug exposure that could be employed in future clinical trials. [ABSTRACT FROM AUTHOR]
- Subjects :
- CELL lines
CANCER cells
CELL communication
VITAMIN D
CELLULAR signal transduction
Subjects
Details
- Language :
- English
- ISSN :
- 19326203
- Volume :
- 19
- Issue :
- 5
- Database :
- Complementary Index
- Journal :
- PLoS ONE
- Publication Type :
- Academic Journal
- Accession number :
- 177375700
- Full Text :
- https://doi.org/10.1371/journal.pone.0303470